gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · MRNAHealthcareBiotechnology

Moderna, Inc. Common Stock (MRNA)

$258.38+13.11%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$258.38▲ 987.92% in range
Earnings Jul 31, 2026Earnings May 7, 2026Earnings May 1, 2026
Nov 4, 2025Low $22.36 · High $258.38Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Moderna closed at $258.38 on Nov 4, up 13.11% — matching its 52-week closing high. Volume of 14.8M shares was 0.80× its 20-day average (below normal).

Split-adjusted performance: +37.8% over one month, +429.6% over six months, +937.3% over one year.

In the quarter ended Jun 30, 2026, revenue was $145M, up 2.1% from a year earlier, with a net margin of -539.3%.

Short interest was 32.6M shares at the Oct 15 settlement, up 5.6% from the prior report (9.0% of float, 1.8 days to cover).

After its Jul 31 report (EPS beat estimates by 3.0%), the stock moved -4.8% from the close before to the close after.

The next earnings report is scheduled for Nov 6, 2026.

Market cap$103.15B399.2M shares
Revenue · quarter$145.0M+2.1% YoY
Diluted EPS$-1.97—
P/E · TTM—P/S 46.3×
Net margin-539.3%Gross 35.9%
Dividend yieldNone
52-week range22.36 – 258.380.0% from high
Volume14.8M0.80× 20-day avg
Volatility · 60d231.0%Annualised
Short % of float9.0%1.8 days to cover
Net cash$4.54BCash $5.14B
Next earningsNov 6Nov 6, 2026
Split-adjusted performance
1W +20.6%1M +37.8%3M +379.7%6M +429.6%YTD +776.2%1Y +937.3%3Y +248.8%5Y −24.2%

Earnings reactions

History →
Jul 31−4.8%
May 7+11.4%
May 1+3.0%

Close before the report to close after it.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum99
Revenue growth41
Net margin41
Value (low P/E)—
Size99

Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.

Short interest

Details →
Shares short32.6M+5.6% vs prior
Days to cover1.8Settled Oct 15
% of float9.0%
Short vol. 10d58.8%of daily volume

Closest peers by size in Biotechnology

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
MRNAModerna$258.38+13.11%+429.6%+2.1%−539.3%—$103.15B
GILDGilead Sciences$174.48+4.19%+28.0%+6.8%29.3%—$216.41BCompare
RVMDRevolution Medicines$199.70+2.82%+32.2%———$42.80BCompare
AMGNAmgen$478.48+3.73%+44.5%+9.5%23.6%29.6$258.68BCompare
BIIBBiogen$254.46+2.22%+33.4%+10.6%−0.7%108.2$37.61BCompare
EXELExelixis$72.75+0.61%+49.4%+10.2%33.1%20.1$17.75BCompare
NBIXNeurocrine Biosciences$166.05+0.73%+12.9%+41.2%18.4%24.0$16.88BCompare
HALOHalozyme Therapeutics$130.34+1.34%+96.4%+47.7%47.8%35.8$14.79BCompare
KYMRKymera Therapeutics$136.25+7.21%+58.0%−100.0%——$11.63BCompare

News about Moderna

All news →
Could Investing in Moderna's Stock Double Your Money?The Motley Fool · 1d ago▲ PositiveBuy Moderna Stock Before Q3 Earnings? Here's What to KnowZacks Investment Research · 2d agoNeutralIf Moderna's CEO Is Right, the Stock's Rally Could Just Be Getting StartedThe Motley Fool · 2d ago▲ PositiveStock Split Watch: Is Moderna Next?The Motley Fool · 2d ago▲ PositiveGSK vs. Moderna: Which Large-Cap Biotech Stock Offers More Growth?Zacks Investment Research · 6d agoNeutral

Quick answers

What does Moderna do?
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020.
What is MRNA's market cap?
$103.15B, based on the Nov 4 close of $258.38.
Does Moderna pay a dividend?
No regular cash dividend has been paid in the last year.
How much of MRNA is sold short?
32.6M shares, 9.0% of float, as of Oct 15, 2026.
When does Moderna report earnings?
The next report is scheduled for Nov 6, 2026.
What sector is MRNA in?
Healthcare, in the Biotechnology industry.

About Moderna

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

HQ: Cambridge, MA4,700 employeesListed Dec 7, 2018modernatx.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology